Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02608684
Title A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Cedars-Sinai Medical Center

fallopian tube carcinoma

ovarian carcinoma

peritoneal carcinoma


Cisplatin + Gemcitabine + Pembrolizumab

Age Groups: adult
Covered Countries USA

No variant requirements are available.